Has Jennifer Harvey, NP received payments from drug or device companies?

Yes. Drug and device makers reported $5,111 in general payments to Jennifer Harvey, NP across 281 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jennifer Harvey, NP did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jennifer Harvey, NP come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jennifer Harvey, NP

Gerontology · Slidell, LANPI 1427595131

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,111in general payments, 2019–2025

Across 281 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$571
Johnson & Johnson$401
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$383
Irhythm Technologies, Inc.$369
Merck$356
E.r. Squibb & Sons, L.L.C.$337
plus $3K from 23 others

What the payments were for

Food & beverage$5,111100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	33	$571
Johnson & Johnson	29	$401
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	24	$383
Irhythm Technologies, Inc.	23	$369
Merck	20	$356
E.r. Squibb & Sons, L.L.C.	20	$337
Esperion Therapeutics, Inc.	18	$321
Sanofi-aventis U.S. LLC	18	$313
Novartis	19	$265
Inspire Medical Systems, Inc.	4	$251
Abbott	8	$186
Kestra Medical Technology Services, Inc.	8	$166
Amgen	10	$158
Revance Therapeutics, Inc.	1	$141
Bayer	9	$136
Boston Scientific	5	$119
Novo Nordisk	6	$114
Baxter Healthcare	2	$91
AstraZeneca	5	$82
Boehringer Ingelheim	5	$82
Kiniksa Pharmaceuticals, Ltd.	3	$59
Amarin Pharma, Inc.	2	$36
Kiniksa Pharmaceuticals International, PLC	2	$33
Actelion Pharmaceuticals US, Inc.	2	$32
Abiomed	1	$28
Edwards Lifesciences	1	$25
Tactile Systems Technology Inc	1	$21
Itamar Medical Inc	1	$20
GSK	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DAXXIFY$141
Inspire$135

How this compares

$5,111 in reported general payments places this provider in the 90th percentile of 64 gerontology providers in Louisiana.

See all gerontology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$22,265

Medicare patients

261

Services billed

347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	299	$321,726
EntrestoSacubitril/Valsartan	63	$92,434
XareltoRivaroxaban	78	$69,610
Repatha SureclickEvolocumab	56	$40,809
JardianceEmpagliflozin	23	$33,085
MounjaroTirzepatide	12	$27,518
MultaqDronedarone Hcl	24	$26,597
Ranolazine ErRanolazine	119	$7,134
Metoprolol Succinate	498	$6,603
Amiodarone Hcl	85	$2,938
Losartan Potassium	282	$2,659
Isosorbide Mononitrate ErIsosorbide Mononitrate	285	$2,639
Atorvastatin Calcium	321	$2,521
Rosuvastatin Calcium	250	$2,501
ClopidogrelClopidogrel Bisulfate	269	$2,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$571	$321,726299 claims
NovartisEntresto	$265	$92,43463 claims
Johnson & JohnsonXarelto	$401	$69,61078 claims
Boehringer IngelheimJardiance	$82	$33,08523 claims
Sanofi-aventis U.S. LLCMultaq	$313	$26,59724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 64 gerontology providers in Louisiana.